|
Originally published In Press as doi:10.1074/jbc.M106919200 on September 17, 2001
J. Biol. Chem., Vol. 276, Issue 45, 42610-42617, November 9, 2001
Src Family Kinases Mediate Epithelial Na+ Channel
Inhibition by Endothelin*
Elaine S.
Gilmore ,
M. Jackson
Stutts, and
Sharon L.
Milgram ¶
From the Cystic Fibrosis/Pulmonary Research and
Treatment Center and Department of Cell and Molecular
Physiology, University of North Carolina at Chapel Hill,
Chapel Hill, North Carolina 27599
Received for publication, July 23, 2001, and in revised form, September 14, 2001
 |
ABSTRACT |
The epithelial Na+ channel
(ENaC) is implicated in the pathogenesis of salt-sensitive
hypertension. Recent evidence from animal models suggests that the
vasoactive peptide, endothelin (ET-1), may be an important negative
regulator of ENaC in vivo. We investigated the signaling
pathway involved in endothelin-mediated ENaC inhibition. Experiments
were performed in NIH 3T3 cells stably expressing genes for the three
( , , and ) ENaC subunits. In whole cell patch clamp
experiments, we found that ET-1 treatment induced a
dose-dependent decrease in amiloride-sensitive currents.
Using receptor-specific antagonists, we determined that the effects of
ET-1 were attributed to activation of the ETB receptor.
Moreover, the inhibitory effect of ET-1 on ENaC could be completely
blocked when cells were pretreated with the selective Src family kinase inhibitor, PP2. Further studies revealed that basal Src family kinase
activity strongly regulates ENaC whole cell currents and single channel
gating. These results suggest that Src family kinases lie in a
signaling pathway activated by ET-1 and are components of a novel
negative regulatory cascade resulting in ENaC inhibition.
 |
INTRODUCTION |
Endothelin (ET)1 1, a
potent vasoactive peptide originally described as an endothelial
cell-derived factor, is the founding member of a family of related
21-amino acid peptides (1, 2). Each endothelin (ET-1, ET-2, and ET-3)
is encoded by a distinct gene and is processed from an inactive
precursor via two proteolytic cleavages to generate a biologically
active peptide (3, 4). Endothelins are synthesized in many cell types,
including endothelial, epithelial, fibroblast, and cardiac muscle
cells, and function as autocrine or paracrine factors to regulate
different cellular processes (1, 5-7). The two endothelin receptors,
ETA and ETB, are broadly expressed with
overlapping, but distinct, distributions (8-11). ETA and
ETB are heterotrimeric G protein-coupled receptors (GPCRs)
that can couple with multiple G subunits, depending on cell type
(12-14). In addition, ET receptors stimulate the activity of
nonreceptor tyrosine kinases in some cells (5, 15, 16). Although this
activation is generally thought to mediate the mitogenic effects of
endothelins, acute activation of NHE3 via ET-1 is blocked ~50% by
tyrosine kinase inhibitors (17, 18). The ET-mediated activation of NHE3
occurs specifically via ETB receptors (19).
Recent evidence indicates that renal ETB receptors may be
important for sodium handling. The function of ETB has been
examined in rats with naturally occurring mutation of the
ETB gene. These studies indicate that ETB plays
an essential role in development of enteric neurons because absence of
functional ETB receptors causes perinatal lethality
resulting from megacolon (20, 21). Gariepy et al. (22)
rescued this phenotype by specifically expressing ETB only
in adrenergic neurons using the dopamine -hydroxylase promoter (22).
On high salt diets, these rats developed salt-sensitive hypertension,
which was restored to normal when animals were treated with amiloride,
a potent inhibitor of the epithelial Na+ channel (ENaC)
(22, 23). These data indicate that endothelin, acting on
ETB receptors, mediates tonic inhibition of ENaC, and that
this inhibition may be required for the maintenance of blood pressure.
ENaC, the product of three distinct genes ( , , and ), is a low
conductance Na+-selective channel that provides the
rate-limiting step in electrogenic Na+ transport across the
apical membrane of many epithelial tissues including the distal nephron
(24-26). Analysis of two human disorders, Liddle syndrome and
pseudohypoaldosteronism type 1, indicates that ENaC in renal epithelia
plays a critical role in salt homeostasis and the control of blood
pressure (27-29). Although all pathways that regulate apical membrane
Na+ transport via ENaC are not known, several hormones
stimulate ENaC activity or expression (30, 31). For example,
aldosterone acts on cytosolic mineralocorticoid receptors to potently
stimulate the absorption of Na+ across cells of the distal
nephron and colon (32). Although this stimulation is accomplished in
part via increased transcription of ENaC subunits, aldosterone also
induces the transcription of the serum and glucocorticoid-regulated
kinase (SGK), which activates ENaC (33, 34). In addition, vasopressin
and insulin are known to stimulate the activity or expression of ENaC
in some model systems (35-37). In contrast, few hormonal pathways that
potently inhibit ENaC activity have been described.
Evidence that rats and mice lacking functional ETB
receptors develop salt-sensitive hypertension supports a role for ET-1 inhibition of ENaC activity. In A6 cells, a Xenopus model of
the distal nephron, ET-1 dramatically down-regulates ENaC activity, although the pathway linking ETB receptors to ENaC was not
identified (38). Therefore, we sought to identify the signaling pathway linking activation of ET receptors to inhibition of ENaC in mammalian cells. We found that ETB receptors act via Src family
kinases to potently inhibit ENaC open probability. This provides a
novel mechanism of ENaC regulation and explains the inhibitory
influence of ETB on ENaC activity. The identification of
signaling proteins that potently inhibit Na+ absorption in
the distal nephron could potentially provide additional therapeutic
targets for the treatment of human hypertension.
 |
EXPERIMENTAL PROCEDURES |
Cell Culture--
Experiments were performed using NIH 3T3 cells
infected with retrovirus encoding cDNAs for rat   ENaC
subunits (39). Clones stably expressing ENaC subunits were maintained
in a humidified incubator with 5% CO2, in Dulbecco's
modified Eagle's medium (DMEM) with 10% bovine calf serum, 10 µM amiloride, 100 units/ml penicillin, 0.1 mg/ml
streptomycin, 300 µg/ml G418, and 1 µg/ml puromycin. Cells for
patch clamp experiments were grown on 35-mm culture dishes in standard
media and were treated with 2 mM sodium butyrate and 1 µM dexamethasone 24 h prior to recording to induce
ENaC expression (39). Cells used for biochemical experiments were maintained at subconfluent states and were moved into serum-free media
at least 24 h prior to study.
Electrophysiology--
NIH 3T3 cells expressing   rat
ENaC subunits were used in patch clamp analyses. Patch pipettes were
pulled from glass capillary tubes using a microelectrode puller and
fire-polished to achieve electrode resistances of 5-8 megohms. Pipette
(intracellular) solutions for whole cell patch clamp experiments
contained, in mM: 120 Tris aspartate, 3 Mg-ATP, 0.3 ADP,
0.1 CaCl2, 7 MgCl2, and 1 EGTA. Additionally,
phosphorylated (activating) or nonphosphorylated peptides (control;
Calbiochem) modeled on the amino acid sequence of the Src kinase
carboxyl terminus (amino acid residues 521-533) were used where
indicated, to modulate the activity of endogenous Src family kinases
(40). The peptides were dissolved in the whole cell pipette solution at
a final concentration of 10 µM. The standard bath
solution for whole cell experiments was composed of, in mM:
150 lithium aspartate, 5 TES, 2 MgCl2, and 1 CaCl2. As indicated, amiloride (final concentration of 10 µM) was added to the bath solution during whole cell recordings.
Whole cell and single channel currents were recorded with an Axopatch
1C amplifier (Axon Instruments). Data was acquired at 2 kHz and
filtered at 200 Hz during whole cell recordings (50 Hz for single
channel recordings) using a low pass four-pole Bessel filter. Data
acquisition and subsequent analyses for both whole cell and single
channel experiments were performed using the pClamp 8.0 software
package (Axon Instruments).
For whole cell patch clamp experiments, cells were voltage-clamped at 0 mV and pulsed to 40 mV every 100 ms for 400-ms intervals. This
sequence was repeated for 180 s. Next, cells were voltage clamped
at 0 mV and pulsed for 600 ms from 160 mV to +20 mV, in 20-mV
increments. Current-voltage (IV) curves were generated from average
current measurements starting 200 ms after each voltage pulse. Whole
cell amiloride-sensitive currents (Iamil) were calculated from the difference in current in the presence and absence of 10 µM amiloride.
Single channel traces were recorded in the cell-attached conformation.
The pipette solution for single channel studies contained, in
mM: 280 lithium aspartate, 2 MgCl2, 5 TES, and
0.1 CaCl2. The bath solution contained, in mM:
150 Tris gluconate, 1 CaCl2, 2 MgSO4, and 5 TES
with CsOH. Cells were preincubated with the Src kinase inhibitor
4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2; 1 µM) or with an inactive control,
4-amino-7-phenylpyrazol[3,4-d]pyrimidine (PP3; 1 µM) for several minutes prior to study (41). Channel open
probability (Po), mean open time (MOT), and mean
closed time (MCT) were calculated from patches containing only single
channel events. Single channel analysis was performed using the pClamp 8.0 software package. To calculate the single channel MOT, the following equation was used.
|
(Eq. 1)
|
T is recording time, Po is the
open probability, and n is the number of channel transitions
during the recording time (38, 42). The single channel MCT was
calculated with the following equation, where the variables are defined
as for Equation 1.
|
(Eq. 2)
|
Western Blots--
NIH 3T3 cells were maintained in media
without serum for 24 h prior to study. Cells were treated with 10 nM ET-1 or vehicle control for 10 min, washed twice in
ice-cold phosphate-buffered saline with phosphatase and protease
inhibitors, and lysed in cold lysis buffer (50 mM Tris, 150 mM NaCl, 0.5% deoxycholate, pH 8.0) with serine/threonine
and tyrosine phosphatase inhibitors (Sigma). Lysates were passed
several times through a 27.5-gauge needle to shear chromosomal DNA.
Homogenates were spun at 313,000 × g, and the soluble
fraction was used for Western blotting and immunoprecipitations. For
phosphotyrosine Western blots, lysates were separated by SDS-PAGE,
transferred to Immobilon-P, and blotted with monoclonal
anti-phosphotyrosine antibody (clone 4G10, Upstate Biotechnology).
In Vitro Kinase Assays--
Kinases were immunoprecipitated from
NIH 3T3 cell lysates using an antibody directed against the conserved
COOH terminus of the Src family kinase sequence that recognizes all Src
kinase family members (rabbit polyclonal antibody; Santa Cruz), or
using antibodies to specific Src family kinases ( -Src kinase,
Oncogene; -Yes kinase, Wako). Lysates were incubated with antibody
at 4 °C for 3-4 h before a 1:1 mixture of Protein A/G-agarose was
added. After 1 h of incubation with Protein A/G-agarose at
4 °C, immunoprecipitates were washed in binding buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.1% Triton X-100, pH 7.4), and resuspended in a
modified pipette solution/kinase assay buffer (150 mM Tris
aspartate, 2 mM MgCl2, 1 mM
CaCl2, 1 mM orthovanadate, 4 µCi of
[ -32P]ATP) with an exogenous Src family kinase
substrate, rabbit muscle enolase (10 µg, Sigma). Additionally, we
tested whether ENaC cytosolic domains were substrates for Src family
kinases. GST-ENaC fusion proteins were generated by subcloning the
cDNAs encoding the NH2- and COOH-terminal subunits of
human , , and ENaC into the pGEX-2TK (Amersham Pharmacia
Biotech) expression vector, which contains an engineered PKA
phosphorylation site. Purified fusion proteins were immobilized on
glutathione-Sepharose in the standard kinase assay buffer described
above and incubated with purified PKA catalytic subunit (Promega) or
purified Src kinase (Upstate Biotechnology). Samples were incubated at
30 °C for 45 min, and reactions were stopped by the addition of
Laemmli sample buffer. Samples were subjected to SDS-PAGE and
visualized by phosphorimage analysis.
 |
RESULTS |
ET-1 Inhibition of ENaC--
We used a previously described NIH
3T3 fibroblast cell model system that stably expresses   ENaC
subunits (39). Similar to those reports, we observed ENaC current
density that ranged from 10 to 30 pA/pF (at 160 mV) under whole cell
patch clamp conditions. Specific ENaC currents were detected as the
difference current (Iamil) in the presence and absence of
10 µM amiloride, a selective ENaC channel blocker (Fig.
1A). Generally, treatment with
amiloride decreased whole cell currents by 50-70%, reflecting the
expression level and activity of ENaC in these cells. ET-1 treatment
markedly inhibited amiloride-sensitive current. Full inhibition of
Iamil was observed in cells treated with 10 nM
ET-1 (Fig. 1B). Concentrations of ET-1 in the range of 1 pM to 10 nM produced a
dose-dependent inhibition of Iamil (Fig.
1C).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 1.
Endothelin-1 potently inhibits
amiloride-sensitive currents. A, raw traces from IV
curves generated from whole cell recordings in the presence and absence
of 10 µM amiloride confirm the expression and activity of
ENaC in NIH 3T3 cells infected with   ENaC genes. The
amiloride-sensitive component ( = Iamil) of the whole
cell currents is calculated from the difference in current before ( )
and after ( ) treatment with amiloride. B, treatment of
NIH 3T3 cells with 10 nM ET-1 ( ) reduces
Iamil significantly below control ( ). Cells were studied
in the presence ( ) or absence ( ) of 10 nM ET-1 for
3-8 min. Results are average currents ± S.E. for six experiments
under each condition. C, ET-1 inhibition of ENaC is
dose-dependent. Cells were treated with 1 pM,
100 pM, or 10 nM ET-1 as in B, and
full IV curves were generated. Shown is Iamil for
ET-1-treated cells expressed as a percentage of the control (no
treatment) amiloride-sensitive current at 120 mV. Results represent
the average currents ± S.E. for four to six experiments.
Statistics were performed using Student's t test (**,
p < 0.005; ***, p < 0.0005).
|
|
ET-1 Activation of ETB Inhibits ENaC--
The ET-1
concentration that resulted in 50% inhibition of Iamil was
~50 pM, in a range consistent with ET-1 activation of ETB receptors. To test this possibility, cells were
pretreated with 1 µM BQ-788, a selective ETB
receptor antagonist. Under these conditions, BQ-788 prevented the
inhibition of ENaC currents by 100 pM ET-1 (Fig.
2A). In contrast, 100 pM ET-1 was fully inhibitory in the presence of 1 µM BQ-123, a selective ETA receptor
antagonist (Fig. 2B). These results demonstrate that, in NIH
3T3 cells, ETB receptor signaling is responsible for ET-1
inhibition of ENaC.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 2.
ETB receptors mediate ET-1
inhibition of ENaC. A, whole cell currents were
recorded from cells treated with 100 pM ET-1 in the
presence ( ) or absence ( ) of 1 µM BQ-788, a
selective ETB receptor antagonist. Control cells ( ) were
treated with vehicle alone. In the presence of BQ-788, ET-1 did not
significantly alter Iamil. Results are the average ± S.E. of six experiments. B, whole cell currents were
recorded from cells treated with 100 pM ET-1 in the
presence ( ) or absence ( ) of 1 µM BQ-123, a
selective ETA antagonist. Control cells ( ) were treated
with vehicle alone. In the presence of BQ-123, ET-1 fully inhibited
Iamil. Results are the average ± S.E. of four
experiments.
|
|
Src Inhibitor Prevents ET-1 Inhibition of ENaC--
We have
demonstrated previously that Src family kinases potently inhibit ENaC
when coexpressed in Xenopus
oocytes.2 Therefore, we
investigated whether Src family kinases were involved in mediating the
effects of ET-1 on ENaC. We used a cell-permeable specific Src family
kinase inhibitor, PP2, in whole cell patch clamp experiments. PP2
competes with ATP for binding to Src family kinases (41). In in
vitro kinase assays, purified Src kinase did not phosphorylate a
known substrate, enolase, in the presence of 1 µM PP2
(Fig. 3A, lane 2).
The negative control compound PP3 shares a similar structure but does
not affect Src kinase activity and did not inhibit the phosphorylation
of enolase (Fig. 3A, lane 3). Cells were
incubated in bath solutions containing 1 µM either PP2 or
PP3 and subsequently treated with 100 pM ET-1. In cells incubated in PP3, ET-1 inhibited Iamil as observed
previously (Fig. 3B). In contrast, in cells pretreated with
PP2, Iamil was not inhibited by 100 pM ET-1.
This observation implicates Src family kinase activity in the
inhibition of ENaC by ET-1.

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 3.
Src family kinase inhibitors prevent ET-1
inhibition of ENaC. A, in vitro kinase
assays demonstrate the efficacy of PP2, a specific Src family kinase
inhibitor. Purified, active Src kinase was incubated with a Src
substrate, enolase, and [ -32P]ATP in a modified
pipette solution buffer. Under control conditions, Src kinase
phosphorylated enolase (lane 1). In the presence
of 1 µM PP2, Src phosphorylation of enolase was inhibited
(lane 2). Incubation with 1 µM PP3,
an inactive analogue of PP2, did not interfere with Src phosphorylation
of enolase (lane 3). Lanes
4 and 5 are reactions performed without enolase
or Src kinase, respectively. Results are representative of three
separate experiments. B, whole cell currents were recorded
from cells treated with 100 pM ET-1 alone ( ) or
following pretreatment with 1 µM PP2 ( ) or PP3 ( ).
Src family kinase inhibition by PP2 completely prevented ET-1
inhibition of Iamil, whereas ET-1 was fully inhibitory in
the presence of PP3. Results are the average ± S.E. of five
experiments. C, NIH 3T3 cells were treated with 10 nM ET-1 for 10 min and then lysed. Proteins were separated
by SDS-PAGE and transferred to Immobilon-P. Total cellular tyrosine
phosphorylation was assessed by Western blot using anti-phosphotyrosine
antiserum (monoclonal antibody clone 4G10). An increase in total
cellular tyrosine phosphorylation was associated with ET-1 treatment.
Results are representative of three separate experiments. D,
NIH 3T3 cells were treated with 10 nM ET-1 for 10 min, then
lysed and immunoprecipitated with 2 µg of -Src family kinase
antisera or rabbit IgG. Immunoprecipitates were subjected to in
vitro kinase assays, and Src family kinase activity was assessed
by phosphorylation of enolase. Lane 1 represents
basal Src family kinase activity (no ET-1 treatment), which is enhanced
upon stimulation with 10 nM ET-1 (lane
2). Pretreatment with PP2 blocked Src phosphorylation of
enolase (lane 3). Lanes
4-6 are corresponding IgG controls. Results are
representative of three separate experiments.
|
|
To demonstrate biochemically that Src family kinases are involved in
ET-1 signaling, we examined changes in phosphotyrosine levels in
response to ET-1 stimulation. Cells were treated with 10 nM
ET-1 for 10 min, lysed, subjected to SDS-PAGE, and transferred to
membranes. Total cell lysates were blotted with anti-phosphotyrosine antibody (monoclonal antibody clone 4G10; Fig. 3C). We
observed a dramatic increase in tyrosine phosphorylation in response to ET-1. In particular, tyrosine phosphorylation of ~85-, 65-, 48-, and
43-kDa proteins were enhanced by ET-1 treatment. Additionally, in
vitro kinase assays measuring the activity of Src family kinases show a significant increase in kinase activity in cells treated with 10 nM ET-1 (72 ± 20% increase over control;
p < 0.05; Fig. 3D). These results indicate
that ET-1 signaling activates tyrosine kinase pathways that include Src
family kinases.
Activation of Endogenous Src Family Kinases Inhibit ENaC--
To
further show that activation of Src family kinases mediates inhibition
of ENaC, we used peptides modeled on the conserved Src family kinase
COOH terminus to activate the endogenous kinases. c-Src is inactivated
by phosphorylation of tyrosine 527, by COOH-terminal Src kinase (CSK; Ref. 43). Intramolecular
interactions between the Src homology 2 domain and this phosphotyrosine
residue (Tyr527) maintain c-Src kinase in an inactive
state. Introduction of phosphorylated peptides containing the sequence
of the Src carboxyl terminus disrupts the intramolecular interactions
that hold the kinase in the folded, inactive state. Addition of
activating phosphorylated peptide to c-Src and c-Yes kinase-specific
immunoprecipitates significantly increased phosphorylation of enolase
in in vitro kinase assays (Fig.
4A). As a control,
immunoprecipitates incubated with the nonphosphorylated peptide, which
does not compete for Src homology 2 binding, show a low level of
phosphorylation. These assays demonstrate that c-Src and c-Yes kinase
can be activated by the introduction of phosphorylated
carboxyl-terminal tail peptides. In whole cell patch clamp experiments,
activation of endogenous Src family kinases resulted in a significant
decrease in amiloride-sensitive currents (Fig. 4B). Dialysis
of cells with the nonphosphorylated, control peptide did not alter ENaC
activity. These experiments reveal that the cell's endogenous Src
family kinases are poised to potently inhibit ENaC when activated by
appropriate signals.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 4.
Activation of endogenous Src family kinases
decreases ENaC currents. A, endogenous Src or Yes
kinase was specifically immunoprecipitated from NIH 3T3 cell lysates,
and their activities were assessed by in vitro
phosphorylation of enolase. Immunoprecipitates incubated in the
presence of phosphorylated, activating Src tail peptides (P)
show increased phosphorylation of enolase, consistent with stimulation
of Src and Yes kinase activity. Introduction of nonphosphorylated,
control peptides (N) did not affect Src or Yes kinase
activity. B, whole cell amiloride-sensitive currents were
recorded from cells dialyzed with phosphorylated ( ) or
nonphosphorylated ( ) Src tail peptides. In the presence of
activating, phosphorylated peptides, Iamil was
significantly decreased as compared with control ( = no peptide).
Results are average ± S.E. of four experiments.
|
|
Src Family Kinase Inhibitor, PP2, Increases Whole Cell ENaC
Currents and Alters Single Channel Gating--
We have shown that
activation of Src family kinases can dramatically reduce
Iamil (Fig. 4B). However, it is evident that Src family kinase activity exists at a basal level in unstimulated cells
(Fig. 3D). To examine whether this basal level of kinase activity influences ENaC currents, we measured Iamil in the
presence of PP2 and PP3. We found that treatment of cells with 1 µM PP2 significantly increased Iamil over
control (PP3) (Fig. 5). These results
suggest that basal Src family kinase activity mediates tonic inhibition
of ENaC in this model system.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 5.
Inhibition of basal Src family kinase
activity increases whole cell ENaC currents. Whole cell
amiloride-sensitive currents were recorded from cells treated with a
standard bath solution or one containing 1 µM PP2 or PP3.
Results are plotted as a percentage of control (no treatment)
amiloride-sensitive current at 120 mV. Inhibition of basal Src family
kinase activity with PP2 significantly increased Iamil over
control (* p < 0.05). Results are the average ± S.E. of four experiments.
|
|
Previous work in A6 cell lines describes the inhibition of ENaC by ET-1
(38). In that study, ET-1 inhibited ENaC Po and enhanced mean closed time. Therefore, to test whether Src family kinases could mediate similar effects on ENaC in mammalian cells, we
studied ENaC in cell-attached single channel patches in the presence of
PP2 or PP3. A representative experiment is shown in Fig.
6A. Channel openings,
represented by upward deflections in the trace, reveal classical ENaC
characteristics, e.g. low amplitude and slow gating channel
transitions (44). Patches from PP2-treated cells contained ENaC that
were open for extended periods (up to tens of seconds), compared with
patches from PP3-treated cells. The all-points histograms in Fig.
6A are examples of analyses generated from continuous traces
from cells treated with PP2 or PP3 and represent the distribution of
time that single channel patches resided in the closed or open
conformation. Integration of the all-points histograms from the entire
data set (1001 s for PP2, 484 s for PP3) shows that cells
incubated in PP3 display a low ENaC open probability
(Po = 0.0475 ± 0.0249) as compared with
cells treated with PP2 (Po = 0.531 ± 0.150; p < 0.02; Fig. 6B). A careful
analysis of the channel gating kinetics reveals that incubation with
PP2 causes shorter mean closed times (3.42 ± 1.52 s for PP2;
13.7 ± 3.02 s for PP3, p < 0.02) between
channel events. Additionally, we observed an increase in mean open time under PP2 conditions, but this increase did not reach statistical significance (3.69 ± 1.83 s for PP2; 0.531 ± 0.257 s
for PP3, p = 0.125). These data suggest that Src family
kinase inhibition enhances ENaC Po by decreasing
the closed time between channel opening events.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 6.
Inhibition of Src family kinase activity
alters single channel gating in cell-attached patches.
A, single channel recordings were obtained from
cell-attached patches on cells treated with 1 µM PP2 or
PP3. In the presence of the Src family kinase inhibitor, ENaC displayed
a higher open probability (Po) and altered
gating kinetics. All-points histograms were generated from continuous
traces recorded under conditions of PP2 or PP3 treatment. Integration
of the curves shows that Src family kinase inhibition is associated
with increased residency time in the open state. B, open
probability (Po) and channel mean open and
closed times were calculated from single channel recordings of cells
incubated in 1 µM PP2 or PP3 as indicated under
"Experimental Procedures." Inhibition of Src family kinases is
associated with increases in Po (*,
p < 0.02) and mean open time (not statistically
significant) and decreases in average closed times for ENaC (*,
p < 0.02).
|
|
Src Family Kinases Do Not Regulate ENaC by Direct Phosphorylation
of the Channel Subunits--
In several instances, Src family kinases
regulate ion transport by direct phosphorylation of the ion channel or
transporter (53, 54). To investigate this possibility as a mechanism
for the regulation of ENaC by Src family kinases, we incubated purified GST fusion proteins encoding the ENaC subunit cytosolic domains with
purified Src kinase (Fig. 7). The fusion
proteins were generated in-frame with GST from the pGEX-2TK expression
vector, which contains an engineered PKA phosphorylation site. As
expected, each of the immobilized NH2- and COOH-terminal
ENaC fusion proteins were phosphorylated by exogenous PKA. However,
purified, active Src kinase failed to phosphorylate any of the ENaC
cytosolic domain fusion proteins. These results demonstrate that ENaC
subunit cytosolic domains do not serve as Src family kinase substrates
in vitro.

View larger version (58K):
[in this window]
[in a new window]
|
Fig. 7.
Src family kinases do not regulate ENaC by
direct phosphorylation of the channel subunits. Immobilized GST
fusion proteins encoding the NH2- (N) and
COOH-terminal (C) , , and ENaC subunits were
incubated with purified catalytic subunit of PKA or purified Src
kinase. Although each of the GST fusion proteins was phosphorylated by
PKA (lower panel), active Src kinase did not
phosphorylate any of the ENaC subunit cytosolic domains
(upper panel). The faint band observed at 60 kDa
in the upper panel is Src kinase
autophosphorylation.
|
|
 |
DISCUSSION |
We have identified Src family kinases as intermediate signaling
proteins in a negative regulatory path for ENaC. Previous reports
linked ET-1 signaling to inhibition of ENaC, but no information existed
concerning the signaling pathway involved (22, 38). Our studies
confirmed previous findings that Src family kinases are activated by
ET-1 signaling (5, 16). We report the novel finding that Src family
kinases potently inhibit ENaC and that this action mediates the
inhibitory effect of ETB on ENaC function. ET-1 is a well
known regulator of systemic blood pressure; as such, its action on
vascular targets has been intensely studied. Additional physiological
roles of this hormone are suggested by ETA and
ETB receptor localization in nonvascular tissues, such as
the nephron (11). Analysis of the ET receptor distribution in the
nephron shows that ETB is expressed at 10-fold higher
levels than ETA, suggesting a dominant role for
ETB in renal tubule epithelial cells (45, 46). Importantly,
adult rats lacking functional ETB receptor activity display
enhanced Na+ reabsorption in the distal nephron,
implicating ETB in regulation of tubular function (22). The
elevated blood pressure in these animals was reversed to normal when
treated with amiloride, a potent inhibitor of ENaC. Our finding that
Src family kinases robustly down-regulate ENaC activity may be critical
to understanding how ETB receptors regulate blood pressure.
Although the phenotype of the ETB receptor-deficient rat is
consistent with an inhibitory effect of ETB on ENaC
activity, the in vivo model does not exclude the role of
indirect effects from ETB in the vasculature, the
possibility that other hormones may be involved, or that the effects
were mediated by changes in ENaC gene expression. Studies in cell
culture models provide systems to examine ET-1 regulation of ENaC in
isolation, separate from the influences of circulating hormones and
complex multisystem regulatory feedback mechanisms. In A6 cells, a
Xenopus model of the distal nephron, ENaC single channel
activity was strongly inhibited by ET-1 (38). This effect was
attributed to the activation of ETB and resulted in
decreases in ENaC Po and increases in channel mean closed time. Our studies in NIH 3T3 cells both confirmed and
extended the previously published results. We found that ET-1 potently
inhibited ENaC in mammalian cells and that this effect was totally
dependent on the activation of Src family kinases (Figs. 1 and 3).
Examination of ENaC at the single channel level showed that Src family
kinase activity decreases ENaC Po and mean open time,
whereas increasing the channel mean closed time (Fig. 6). Because the
regulation of ENaC by ET-1 is robust in cell culture and heterologous
expression systems, it is unlikely that the regulation of ENaC by ET-1
observed in vivo is a secondary consequence of the actions
of other hormones or signals. Instead, the effects of ET-1 on ENaC
regulation are most likely caused by direct activation of intracellular
signal transduction pathways involving Src kinases that link the
receptor to ENaC.
ETA and ETB are GPCRs, but several published
reports show that ET-1 treatment causes a significant increase in
cellular tyrosine phosphorylation and Src kinase activity (5, 47).
There are many examples of cross-talk between GPCRs and tyrosine
kinases, for instance Src and the calcium-sensitive tyrosine kinase,
Pyk2, couple lysophosphatidic acid (G i-coupled) and
bradykinin (G q-coupled) receptors with the
mitogen-activated protein kinase pathway (48). Additionally, inhibitors
of tyrosine kinases (herbimycin A) and Src kinases (PP1), block
activation of mitogen-activated protein kinase cascades by thrombin
receptors (G q-coupled) (49, 50). The mechanism
responsible for linking these signaling cascades is not fully
understood, but could involve the activation of
Ca2+-sensitive kinases or direct actions of G-protein
subunits on tyrosine kinase effectors (48, 51). Here, we showed that
treatment of NIH 3T3 cells with 10 nM ET-1 markedly
increased total cellular tyrosine phosphorylation and Src family kinase
activity, in particular (Fig. 3, C and D).
Further, the inhibitory effects of ET-1 on ENaC activity could be
completely blocked if cells were pretreated with Src family kinase
inhibitors (Fig. 3B). Together, these data strongly argue
that Src family kinases contribute to the ET-1 signaling cascade. Src
family kinases are potent mitogenic agents, and ET-1-mediated gene
expression of atrial natriuretic peptide in primary cardiomyocytes is
Src kinase-dependent (5). However, the time frame of our
observations eliminates the possibility that changes in expression of
ENaC regulatory proteins accounts for the acute effects of Src family
kinases on ENaC. Here, we describe a paradigm in which ET-1 rapidly
alters ion transport via a transcription-independent mechanism. This
effect is similar to previous reports of ET-1 activation of the
Na+/H+ exchanger 3 (NHE3), in which ET-1
effects (via ETB) were blocked ~50% by tyrosine kinase
inhibitors (17). Additionally, regulation of Na-HCO3
co-transport by carbachol through activation of muscarinic receptors
was completely inhibited by the Src family kinase inhibitor, PP1 (52).
These examples provide important evidence that cross-talk between GPCRs
and tyrosine kinases can have immediate effects on ion transport, in
addition to long term mitogenic effects on gene transcription.
Moreover, our in vitro studies suggest that the phenotype of
the ETB-deficient rat and mouse may not be explained solely
by changes in the expression of ENaC subunit genes or by the
involvement of other hormonal systems.
The mechanism by which Src family kinases inhibit ENaC activity remains
to be determined. Our single channel data clearly show changes in
channel open probability consistent with inhibition of whole cell
currents by Src family kinases (Fig. 4). We found that inhibition of
Src family kinase activity caused ENaC channels to display short
average closed times (Fig. 6). This suggests that active Src family
kinases tonically inhibit ENaC by altering the channel gating. The low
ENaC Po associated with Src activation is
consistent with the strong inhibition of whole cell currents. Our
experiments do not exclude the possibility that Src kinase activity
also regulates the number of ENaC channels on the cell surface.
However, our single channel data showed a strong inhibition of channel
open probability that is sufficient to alone account for the inhibition
of whole cell currents by Src family kinases.
We find that Src family kinase activity is required for the inhibition
of ENaC by ET-1. Therefore, it will be crucial to identify the relevant
proteins that are downstream of Src family kinases to further define
the molecular mechanism of this inhibition. Previous reports describing
ion transport regulation by Src family kinases include direct
phosphorylation of channels or transporters (53, 54). This seems
unlikely in the case of ENaC. The in vitro phosphorylation
of ENaC subunits has been investigated; however, only
phosphoserine/threonine, but not phosphotyrosine residues were observed
(55, 56). Moreover, the ENaC subunit cytosolic domains do not contain
consensus sites for Src kinase phosphorylation. Our data (Fig. 7)
support these findings and demonstrate that ENaC cytosolic domains are
not substrates for Src kinase in vitro. Therefore, it is
likely that Src family kinases inhibit ENaC by an indirect mechanism.
These findings are similar to the regulation of ENaC by the
serum-glucocorticoid-regulated kinase (SGK), where SGK activation
increases ENaC activity by enhancing cell-surface expression (34). When
coexpressed in Xenopus laevis oocytes, SGK increases ENaC
activity by stimulating the translocation of ENaC channels to the cell
surface in a kinase-dependent manner (34). The mechanism
that accounts for enhanced cell-surface expression is unknown, but
similar to Src, SGK does not directly phosphorylate ENaC and the target
of its kinase activity is unidentified (56). Our results, taken
together with these findings on SGK regulation of ENaC, make it clear
that unidentified molecular mechanisms exist for control of
Na+ conductance. These mechanisms may vary importantly with
cell type and with the upstream hormonal signal involved. Clearly there are intermediary proteins that are required for the regulation of ENaC
by SGK and Src family kinases, identification of these proteins will be
the subject of future studies.
Several general mechanisms can be envisioned by which Src family
kinases may act to indirectly inhibit ENaC activity. First, Src family
kinase activation may modulate the activity of a serine/threonine kinase. Insulin stimulates receptor tyrosine kinase activity, increases
serine/threonine phosphorylation of and ENaC, and increases
ENaC activity (55). Therefore, it is possible that Src kinases may
enhance or suppress the activity of a serine/threonine kinase, which in
turn, modulates ENaC activity. Second, Src family kinase activation may
alter the activity of a phosphatase that subsequently dephosphorylates
the channel or an associated regulator. Third, Src family kinases may
induce cytoskeletal rearrangements that affect the association of
stimulatory or inhibitory proteins with ENaC. Finally, the target of
Src family kinase activity could be an ENaC-associated cytosolic
protein, whose phosphorylation state influences its association with
the channel. Binding or release from the channel may potentially alter
channel gating. Given the complexity of ENaC regulation, any of these
models could account for the effects of Src family kinases.
The involvement of ET-1 and ETB in the genesis of
salt-sensitive hypertension may provide new insights into the molecular pathophysiology of renal disease. Our novel finding that Src family kinases are required for endothelin-mediated inhibition of ENaC provides further understanding of Na+ transport regulation,
with potential implications for elucidating causes of human
hypertension. It will be intriguing to examine the hypertensive
population for variations in ET-1, ETB, and Src family
kinase activities in the nephron. Such alterations may help to
understand the mechanisms of salt-sensitive hypertension and/or
essential hypertension. In additional, identifying the Src family
kinase members (Src, Yes, Fyn, etc.) that mediate these effects
in vivo could provide insights into understanding the functional specificity of Src family kinase signaling. Our
identification of Src family kinases as intermediaries of ET-1
modulation of ENaC provides another potential therapeutic target for
the treatment of human hypertension.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Wanda O'Neal for kind help in
the generation of pGEX-2TK ENaC subunit constructs. We thank Mary
Lang-Furr for cell culture assistance and members of the Milgram and
Stutts laboratories for advice, support, and encouragement.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grant HL63755 (to S. L. M. and M. J. S.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Dept. of Cell and
Molecular Physiology, University of North Carolina, CB 7545, Chapel
Hill, NC 27599. Tel.: 919-966-9792; Fax: 919-966-6927; E-mail:
milg@med.unc.edu.
Published, JBC Papers in Press, September 17, 2001, DOI 10.1074/jbc.M106919200
2
Donaldson, S. H., Boucher, R. C., and Stutts, M. J., unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
ET, endothelin;
ENaC, epithelial Na+ channel;
ETA, endothelin-type A receptor;
ETB, endothelin-type B
receptor;
GPCR, G-protein-coupled receptor;
I, current;
IAmil, amiloride current;
IV, current-voltage;
MCT, mean
closed time;
MOT, mean open time;
NHE3, Na+/H+
exchanger isoform 3;
SGK, serum and glucocorticoid-regulated kinase;
Po, open probability;
PP2, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine;
PP3, 4-amino-7-phenylpyrazol[3,4-d]pyrimidine;
GST, glutathione S-transferase;
PKA, cAMP-dependent
protein kinase;
PAGE, polyacrylamide gel electrophoresis;
TES, 2-{[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino}ethanesulfonic
acid.
 |
REFERENCES |
| 1.
|
Yanagisawa, M.,
Kurihara, H.,
Kimura, S.,
Tomobe, Y.,
Kobayashi, M.,
Mitsui, Y.,
Yazaki, Y.,
Goto, K.,
and Masaki, T.
(1988)
Nature
332,
411-415[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Inoue, A.,
Yanagisawa, M.,
Kimura, S.,
Kasuya, Y.,
Miyauchi, T.,
Goto, K.,
and Masaki, T.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
2863-2867[Abstract/Free Full Text]
|
| 3.
|
Masaki, T.,
Yanagisawa, M.,
Inoue, A.,
Kimura, S.,
and Goto, K.
(1990)
Jpn. Circ. J.
54,
1221-1225[Medline]
[Order article via Infotrieve]
|
| 4.
|
Kimura, S.,
Kasuya, Y.,
Sawamura, T.,
Shinimi, O.,
Sugita, Y.,
Yanagisawa, M.,
Goto, K.,
and Masaki, T.
(1989)
J. Cardiovasc. Pharmacol.
13,
S5-S7; Discussion S18
|
| 5.
|
Kovacic, B.,
Ilic, D.,
Damsky, C. H.,
and Gardner, D. G.
(1998)
J. Biol. Chem.
273,
35185-35193[Abstract/Free Full Text]
|
| 6.
|
Saenz de Tejada, I.,
Mueller, J. D.,
de Las Morenas, A.,
Machado, M.,
Moreland, R. B.,
Krane, R. J.,
Wolfe, H. J.,
and Traish, A. M.
(1992)
J. Urol.
148,
1290-1298[Medline]
[Order article via Infotrieve]
|
| 7.
|
Shichiri, M.,
Hirata, Y.,
Nakajima, T.,
Ando, K.,
Imai, T.,
Yanagisawa, M.,
Masaki, T.,
and Marumo, F.
(1991)
J. Clin. Invest.
87,
1867-1871
|
| 8.
|
Masuda, Y.,
Miyazaki, H.,
Kondoh, M.,
Watanabe, H.,
Yanagisawa, M.,
Masaki, T.,
and Murakami, K.
(1989)
FEBS Lett.
257,
208-210[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Mizuguchi, T.,
Nishiyama, M.,
Moroi, K.,
Tanaka, H.,
Saito, T.,
Masuda, Y.,
Masaki, T.,
de Wit, D.,
Yanagisawa, M.,
and Kimura, S.
(1997)
Br. J. Pharmacol.
120,
1427-1430[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Davenport, A. P.,
Nunez, D. J.,
Hall, J. A.,
Kaumann, A. J.,
and Brown, M. J.
(1989)
J. Cardiovasc. Pharmacol.
13,
S166-S170
|
| 11.
|
Takayanagi, R.,
Ohnaka, K.,
Takasaki, C.,
Ohashi, M.,
and Nawata, H.
(1991)
J. Cardiovasc. Pharmacol.
17,
S127-S130
|
| 12.
|
Imamura, T.,
Ishibashi, K.,
Dalle, S.,
Ugi, S.,
and Olefsky, J. M.
(1999)
J. Biol. Chem.
274,
33691-33695[Abstract/Free Full Text]
|
| 13.
|
Emala, C. W.,
Liu, F.,
and Hirshman, C. A.
(1999)
Am. J. Physiol.
276,
L564-L570[Abstract/Free Full Text]
|
| 14.
|
Shraga-Levine, Z.,
and Sokolovsky, M.
(2000)
Cell Mol. Neurobiol.
20,
305-317[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Simonson, M. S.,
Wang, Y.,
and Herman, W. H.
(1996)
J. Biol. Chem.
271,
77-82[Abstract/Free Full Text]
|
| 16.
|
Schieffer, B.,
Drexler, H.,
Ling, B. N.,
and Marrero, M. B.
(1997)
Am. J. Physiol.
272,
C2019-C2030[Abstract/Free Full Text]
|
| 17.
|
Chu, T. S.,
Tsuganezawa, H.,
Peng, Y.,
Cano, A.,
Yanagisawa, M.,
and Alpern, R. J.
(1996)
Am. J. Physiol.
271,
C763-C771[Abstract/Free Full Text]
|
| 18.
|
Donowitz, M.,
Janecki, A.,
Akhter, S.,
Cavet, M. E.,
Sanchez, F.,
Lamprecht, G.,
Zizak, M.,
Kwon, W. L.,
Khurana, S.,
Yun, C. H.,
and Tse, C. M.
(2000)
Ann. N. Y. Acad. Sci.
915,
30-42[Medline]
[Order article via Infotrieve]
|
| 19.
|
Chu, T. S.,
Peng, Y.,
Cano, A.,
Yanagisawa, M.,
and Alpern, R. J.
(1996)
J. Clin. Invest.
97,
1454-1462[Medline]
[Order article via Infotrieve]
|
| 20.
|
Hosoda, K.,
Hammer, R. E.,
Richardson, J. A.,
Baynash, A. G.,
Cheung, J. C.,
Giaid, A.,
and Yanagisawa, M.
(1994)
Cell
79,
1267-1276[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Gariepy, C. E.,
Cass, D. T.,
and Yanagisawa, M.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
867-872[Abstract/Free Full Text]
|
| 22.
|
Gariepy, C. E.,
Ohuchi, T.,
Williams, S. C.,
Richardson, J. A.,
and Yanagisawa, M.
(2000)
J. Clin. Invest.
105,
925-933[Medline]
[Order article via Infotrieve]
|
| 23.
|
Kleyman, T. R.,
Sheng, S.,
Kosari, F.,
and Kieber-Emmons, T.
(1999)
Semin. Nephrol.
19,
524-532[Medline]
[Order article via Infotrieve]
|
| 24.
|
Canessa, C. M.,
Schild, L.,
Buell, G.,
Thorens, B.,
Gautschi, I.,
Horisberger, J. D.,
and Rossier, B. C.
(1994)
Nature
367,
463-467[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Ciampolillo, F.,
McCoy, D. E.,
Green, R. B.,
Karlson, K. H.,
Dagenais, A.,
Molday, R. S.,
and Stanton, B. A.
(1996)
Am. J. Physiol.
271,
C1303-C1315[Abstract/Free Full Text]
|
| 26.
|
Barbry, P.,
and Hofman, P.
(1997)
Am. J. Physiol.
273,
G571-G585[Abstract/Free Full Text]
|
| 27.
|
Schild, L.,
Lu, Y.,
Gautschi, I.,
Schneeberger, E.,
Lifton, R. P.,
and Rossier, B. C.
(1996)
EMBO J.
15,
2381-2387[Medline]
[Order article via Infotrieve]
|
| 28.
|
Grunder, S.,
Firsov, D.,
Chang, S. S.,
Jaeger, N. F.,
Gautschi, I.,
Schild, L.,
Lifton, R. P.,
and Rossier, B. C.
(1997)
EMBO J.
16,
899-907[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Schild, L.
(1996)
Nephrologie
17,
395-400[Medline]
[Order article via Infotrieve]
|
| 30.
|
Alvarez de la Rosa, D.,
Canessa, C. M.,
Fyfe, G. K.,
and Zhang, P.
(2000)
Annu. Rev. Physiol.
62,
573-594[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Garty, H.
(2000)
Kidney Int.
57,
1270-1276[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
May, A.,
Puoti, A.,
Gaeggeler, H. P.,
Horisberger, J. D.,
and Rossier, B. C.
(1997)
J. Am. Soc. Nephrol.
8,
1813-1822[Abstract]
|
| 33.
|
Chen, S. Y.,
Bhargava, A.,
Mastroberardino, L.,
Meijer, O. C.,
Wang, J.,
Buse, P.,
Firestone, G. L.,
Verrey, F.,
and Pearce, D.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
2514-2519[Abstract/Free Full Text]
|
| 34.
|
Alvarez de la Rosa, D.,
Zhang, P.,
Naray-Fejes-Toth, A.,
Fejes-Toth, G.,
and Canessa, C. M.
(1999)
J. Biol. Chem.
274,
37834-37839[Abstract/Free Full Text]
|
| 35.
|
Marunaka, Y.,
and Eaton, D. C.
(1991)
Am. J. Physiol.
260,
C1071-C1084[Abstract/Free Full Text]
|
| 36.
|
Canessa, C. M.,
and Schafer, J. A.
(1992)
Am. J. Physiol.
262,
F454-F461[Abstract/Free Full Text]
|
| 37.
|
Marunaka, Y.,
Hagiwara, N.,
and Tohda, H.
(1992)
Am. J. Physiol.
263,
F392-F400[Abstract/Free Full Text]
|
| 38.
|
Gallego, M. S.,
and Ling, B. N.
(1996)
Am. J. Physiol.
271,
F451-F460[Abstract/Free Full Text]
|
| 39.
|
Stutts, M. J.,
Rossier, B. C.,
and Boucher, R. C.
(1997)
J. Biol. Chem.
272,
14037-14040[Abstract/Free Full Text]
|
| 40.
|
Roussel, R. R.,
Brodeur, S. R.,
Shalloway, D.,
and Laudano, A. P.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
10696-10700[Abstract/Free Full Text]
|
| 41.
|
Hanke, J. H.,
Gardner, J. P.,
Dow, R. L.,
Changelian, P. S.,
Brissette, W. H.,
Weringer, E. J.,
Pollok, B. A.,
and Connelly, P. A.
(1996)
J. Biol. Chem.
271,
695-701[Abstract/Free Full Text]
|
| 42.
|
Yue, G.,
Edinger, R. S.,
Bao, H. F.,
Johnson, J. P.,
and Eaton, D. C.
(2000)
Am. J. Physiol.
279,
C81-C88[Abstract/Free Full Text]
|
| 43.
|
Nada, S.,
Okada, M.,
MacAuley, A.,
Cooper, J. A.,
and Nakagawa, H.
(1991)
Nature
351,
69-72[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Garty, H.,
and Palmer, L. G.
(1997)
Physiol. Rev.
77,
359-396[Abstract/Free Full Text]
|
| 45.
|
Takemoto, F.,
Uchida, S.,
Ogata, E.,
and Kurokawa, K.
(1993)
Am. J. Physiol.
264,
F827-F832[Abstract/Free Full Text]
|
| 46.
|
Karet, F. E.
(1996)
Clin. Sci. (Lond.)
91,
267-273[Medline]
[Order article via Infotrieve]
|
| 47.
|
Haneda, M.,
Kikkawa, R.,
Koya, D.,
Shikano, T.,
Sugimoto, T.,
Togawa, M.,
and Shigeta, Y.
(1995)
J. Am. Soc. Nephrol.
6,
1504-1510[Abstract]
|
| 48.
|
Dikic, I.,
Tokiwa, G.,
Lev, S.,
Courtneidge, S. A.,
and Schlessinger, J.
(1996)
Nature
383,
547-550[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Rao, G. N.,
Delafontaine, P.,
and Runge, M. S.
(1995)
J. Biol. Chem.
270,
27871-27875[Abstract/Free Full Text]
|
| 50.
|
Della Rocca, G. J.,
Maudsley, S.,
Daaka, Y.,
Lefkowitz, R. J.,
and Luttrell, L. M.
(1999)
J. Biol. Chem.
274,
13978-13984[Abstract/Free Full Text]
|
| 51.
|
Luttrell, L. M.,
Hawes, B. E.,
van Biesen, T.,
Luttrell, D. K.,
Lansing, T. J.,
and Lefkowitz, R. J.
(1996)
J. Biol. Chem.
271,
19443-19450[Abstract/Free Full Text]
|
| 52.
|
Robey, R. B.,
Ruiz, O. S.,
Baniqued, J.,
Mahmud, D.,
Espiritu, D. J.,
Bernardo, A. A.,
and Arruda, J. A.
(2001)
Am. J. Physiol.
280,
F844-F850[Abstract/Free Full Text]
|
| 53.
|
MacFarlane, S. N.,
and Sontheimer, H.
(2000)
J. Neurosci.
20,
5245-5253[Abstract/Free Full Text]
|
| 54.
|
Ling, S.,
Woronuk, G.,
Sy, L.,
Lev, S.,
and Braun, A. P.
(2000)
J. Biol. Chem.
275,
30683-30689[Abstract/Free Full Text]
|
| 55.
|
Shimkets, R. A.,
Lifton, R.,
and Canessa, C. M.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
3301-3305[Abstract/Free Full Text]
|
| 56.
|
Chigaev, A.,
Lu, G.,
Shi, H.,
Asher, C.,
Xu, R.,
Latter, H.,
Seger, R.,
Garty, H.,
and Reuveny, E.
(2001)
Am. J. Physiol.
280,
F1030-F1036
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. M. Berger, C. S. Rozendal, C. Schieber, M. Dehler, S. Zugel, H. J. Bardenheuer, P. Bartsch, and H. Mairbaurl
The Effect of Endothelin-1 on Alveolar Fluid Clearance and Pulmonary Edema Formation in the Rat
Anesth. Analg.,
January 1, 2009;
108(1):
225 - 231.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Bhalla and K. R. Hallows
Mechanisms of ENaC Regulation and Clinical Implications
J. Am. Soc. Nephrol.,
October 1, 2008;
19(10):
1845 - 1854.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Bugaj, O. Pochynyuk, E. Mironova, A. Vandewalle, J. L. Medina, and J. D. Stockand
Regulation of the epithelial Na+ channel by endothelin-1 in rat collecting duct
Am J Physiol Renal Physiol,
October 1, 2008;
295(4):
F1063 - F1070.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. A. Drummond, S. C. Grifoni, and N. L. Jernigan
A New Trick for an Old Dogma: ENaC Proteins as Mechanotransducers in Vascular Smooth Muscle
Physiology,
February 1, 2008;
23(1):
23 - 31.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. N. Helms, X.-J. Chen, S. Ramosevac, D. C. Eaton, and L. Jain
Dopamine regulation of amiloride-sensitive sodium channels in lung cells
Am J Physiol Lung Cell Mol Physiol,
April 1, 2006;
290(4):
L710 - L722.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. D. Carattino, R. S. Edinger, H. J. Grieser, R. Wise, D. Neumann, U. Schlattner, J. P. Johnson, T. R. Kleyman, and K. R. Hallows
Epithelial Sodium Channel Inhibition by AMP-activated Protein Kinase in Oocytes and Polarized Renal Epithelial Cells
J. Biol. Chem.,
May 6, 2005;
280(18):
17608 - 17616.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Falin, I. E. Veizis, and C. U. Cotton
A role for ERK1/2 in EGF- and ATP-dependent regulation of amiloride-sensitive sodium absorption
Am J Physiol Cell Physiol,
May 1, 2005;
288(5):
C1003 - C1011.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ohkita, Y. Wang, N. D. T. Nguyen, Y.-H. Tsai, S. C. Williams, R. C. Wiseman, P. D. Killen, S. Li, M. Yanagisawa, and C. E. Gariepy
Extrarenal ETB Plays a Significant Role in Controlling Cardiovascular Responses to High Dietary Sodium in Rats
Hypertension,
May 1, 2005;
45(5):
940 - 946.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. Cohen
SRC family kinases in cell volume regulation
Am J Physiol Cell Physiol,
March 1, 2005;
288(3):
C483 - C493.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Tong and J. D. Stockand
Receptor tyrosine kinases mediate epithelial Na+ channel inhibition by epidermal growth factor
Am J Physiol Renal Physiol,
January 1, 2005;
288(1):
F150 - F161.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Mies, V. Shlyonsky, A. Goolaerts, and S. Sariban-Sohraby
Modulation of epithelial Na+ channel activity by long-chain n-3 fatty acids
Am J Physiol Renal Physiol,
October 1, 2004;
287(4):
F850 - F855.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Huang, E. Gilmore, P. Kultgen, P. Barnes, S. Milgram, and M. J. Stutts
Local Regulation of Cystic Fibrosis Transmembrane Regulator and Epithelial Sodium Channel in Airway Epithelium
Proceedings of the ATS,
January 1, 2004;
1(1):
33 - 37.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. P. Feranchak, G. Kilic, P. A. Wojtaszek, I. Qadri, and J. G. Fitz
Volume-sensitive Tyrosine Kinases Regulate Liver Cell Volume through Effects on Vesicular Trafficking and Membrane Na+ Permeability
J. Biol. Chem.,
November 7, 2003;
278(45):
44632 - 44638.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Blouquit, A. Sari, A. Lombet, M. D'herbomez, E. Naline, R. Matran, and T. Chinet
Effects of Endothelin-1 on Epithelial Ion Transport in Human Airways
Am. J. Respir. Cell Mol. Biol.,
August 1, 2003;
29(2):
245 - 251.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Terres, H. J. Windle, E. Ardini, and D. P. Kelleher
Soluble Extracts from Helicobacter pylori Induce Dome Formation in Polarized Intestinal Epithelial Monolayers in a Laminin-Dependent Manner
Infect. Immun.,
July 1, 2003;
71(7):
4067 - 4078.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Funke-Kaiser, F. Reichenberger, K. Kopke, S.-M. Herrmann, J. Pfeifer, H.-D. Orzechowski, W. Zidek, M. Paul, and E. Brand
Differential binding of transcription factor E2F-2 to the endothelin-converting enzyme-1b promoter affects blood pressure regulation
Hum. Mol. Genet.,
February 15, 2003;
12(4):
423 - 433.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|